Price
$75.19
Increased by +1.36%
Dollar volume (20D)
42.36 M
ADR%
3.61
Earnings report date
Aug 5, 2024
Shares float
35.00 M
Shares short
7.71 M [22.03%]
Shares outstanding
47.50 M
Market cap
3.52 B
Beta
1.12
Price/earnings
N/A
20D range
72.30 79.13
50D range
65.50 83.89
200D range
55.02 98.40

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States.

The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.

It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder.

Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation.

The company was incorporated in 2012 and is based in New York, New York.

  • Quarterly earnings
  • Annual earnings
Reported date EPSChange YoY EstimateSurprise
May 6, 24 -1.44
Decreased by -453.85%
-1.20
Decreased by -20.00%
Feb 20, 24 -2.08
Decreased by -47.52%
-1.17
Decreased by -77.78%
Nov 6, 23 -1.32
Decreased by -23.36%
-1.20
Decreased by -10.00%
Aug 7, 23 -1.54
Decreased by -45.28%
-1.22
Decreased by -26.23%
May 8, 23 -0.26
Increased by +74.76%
-1.04
Increased by +75.00%
Feb 27, 23 -1.41
Decreased by -56.67%
-1.14
Decreased by -23.68%
Nov 7, 22 -1.07
Decreased by -15.05%
-1.08
Increased by +0.93%
Aug 9, 22 -1.06
Decreased by -23.26%
-1.21
Increased by +12.40%
  • Quarterly financials
  • Annual financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Mar 31, 24 75.00 M
Decreased by -20.70%
-68.36 M
Decreased by -509.35%
Decreased by -91.14%
Decreased by -668.41%
Dec 31, 23 71.53 M
Increased by +193.50%
-98.65 M
Decreased by -47.76%
Decreased by -137.92%
Increased by +49.65%
Sep 30, 23 57.79 M
Increased by +243.08%
-62.20 M
Decreased by -31.68%
Decreased by -107.62%
Increased by +61.62%
Jun 30, 23 46.70 M
Increased by +429.49%
-67.17 M
Decreased by -56.81%
Decreased by -143.83%
Increased by +70.39%
Mar 31, 23 94.58 M
Increased by +N/A%
-11.22 M
Increased by +72.62%
Decreased by -11.86%
Decreased by N/A%
Dec 31, 22 24.37 M
Increased by +N/A%
-66.76 M
Decreased by -96.50%
Decreased by -273.94%
Decreased by N/A%
Sep 30, 22 16.85 M
Increased by +N/A%
-47.23 M
Decreased by -35.41%
Decreased by -280.39%
Decreased by N/A%
Jun 30, 22 8.82 M
Increased by +N/A%
-42.84 M
Decreased by -32.68%
Decreased by -485.68%
Decreased by N/A%
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY